Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 8.03% | 2.91% | 20.71% |
| 2025 |
|---|
| 20.7% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 8.03% | 2.91% | 20.71% |
| 2025 |
|---|
| 20.7% |
The Oakmark Global Select Fund delivered a 2.91% return in Q4 2025, underperforming the MSCI World Index's 3.12% return, though achieving strong full-year performance of 20.71%. The fund maintains a concentrated global portfolio with 55.6% in the U.S., 31.4% in Europe ex-U.K., and selective emerging market exposure at 3.6%. Healthcare and financials were the strongest performing sectors, while consumer discretionary and staples detracted. Bayer led performance with positive drug trial results for Asundexian and potential Supreme Court review of litigation matters. Alibaba declined despite strong core e-commerce and accelerating cloud growth, pressured by Quick Commerce investment spending. The managers added Sanofi, capitalizing on temporary vaccine market volatility to invest in a company with the blockbuster drug Dupixent and strong R&D pipeline. Portfolio activity included exits from Mercedes-Benz and Roche. The strategy continues focusing on undervalued companies with strong fundamentals where temporary market concerns create attractive entry points for long-term value creation.
The fund focuses on undervalued global companies with strong fundamentals, particularly in pharmaceuticals and technology, where temporary market concerns create opportunities to invest in businesses with long-term growth potential and competitive advantages.
The managers express optimism about pharmaceutical companies with strong R&D pipelines and expect vaccine markets to normalize. They maintain conviction in Chinese technology companies despite near-term headwinds, believing in long-term value creation through AI capabilities and market positioning.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 13 2026 | 2025 Q4 | BABA, BAYRY, CHTR, CNHI, GOOGL, IQV, MBG.DE, RHHBY, SNY | China, Europe, global, healthcare, Pharmaceuticals, technology, value |
BAYN GR BABA SAN FP |
Oakmark Global Select delivered solid Q4 performance driven by healthcare holdings, particularly Bayer's positive drug trial results. The fund added Sanofi during vaccine market volatility, capitalizing on strong fundamentals and Dupixent growth potential. Despite Alibaba's near-term pressure from Quick Commerce investments, managers maintain conviction in Chinese technology positioning for long-term AI-driven value creation. |
| Oct 10 2025 | 2025 Q3 | BABA, CHTR, CNC, CNHI, DASTY, GOOGL, MOH, PRX | AI, Broadband, China, Cloud, Europe, global, technology, value | - | Oakmark Global Select underperformed in Q3 as AI-driven Alibaba gains were offset by Charter Communications broadband weakness. The fund opportunistically added Dassault Systèmes following a 40% decline, viewing the French software leader as attractively valued despite solid fundamentals. Managers maintain conviction in technology positioning and long-term competitive advantages across global holdings. |
| Jun 30 2025 | 2025 Q2 | BABA, BAYRY, BDX, BMW.DE, BN.PA, BNP.PA, COF, DSV.CO, FI, IQV, LLOY.L, PRX.AS | Banking, Electric Vehicles, Europe, Medical Devices, Pharmaceuticals, Trade Policy, value |
BAYRY IQV BDX BMW.DE BNP.PA DSV.CO |
Oakmark Global Select underperformed in Q2 2025 amid tariff-driven volatility but actively repositioned into quality companies at wider discounts. Added BMW, BNP Paribas, Becton Dickinson, and DSV while trimming outperformers. Bayer led contributors on pharma strength and litigation progress. IQVIA detracted on biopharma headwinds. Maintains value-focused approach targeting long-term compounders at attractive valuations. |
| Mar 31 2025 | 2025 Q1 | AIG, AMZN, BABA, DEO, GOOGL, HLT, IQV, LLOY.L, MOH, PHM, SYY | AI, Banking, global, growth, healthcare, technology, undervalued, value |
LLOY.L GOOGL MOH SYY |
Oakmark Global Select delivered exceptional Q1 performance at 8.54% versus -1.79% for MSCI World through disciplined value investing. Strong contributions from Lloyds Banking and new positions in undervalued Molina Healthcare and Sysco Corporation demonstrate the fund's ability to capitalize on market inefficiencies. Geographic diversification and focus on quality businesses trading below intrinsic value drive consistent outperformance. |
| Dec 31 2024 | 2024 Q4 | 005930.KS, BAC, BAYRY, CNC, COF, DEO, ELV, FI, GOOGL, IQV, SCHW | Beverages, consumer, financials, global, healthcare, regulation, value |
COF BAYRY SCHW DEO ELV |
Oakmark Global Select underperformed in Q4 but used volatility to add quality names at discounts. Capital One led gains on deregulation hopes while Bayer dragged on litigation and guidance concerns. New positions in Schwab, Diageo, and Elevance target temporary headwinds in dominant franchises, expecting normalization to drive attractive returns. |
| Sep 30 2024 | 2024 Q3 | 005930.KS, BABA, FI, GOOGL, MBG.DE, PRX.AS | China, financials, global, healthcare, semiconductors, technology |
BABA 005930.KS |
Oakmark Global Select outperformed with an 8.82% quarterly return, driven by Alibaba's rally on Chinese stimulus and strong financials/healthcare performance. Samsung detracted on memory weakness. The concentrated global portfolio maintains conviction in undervalued names with turnaround potential, particularly seeing upside in Alibaba's e-commerce business despite recent gains. |
| Jun 30 2024 | 2024 Q2 | 035420.KS, CNC, CNHI, GOOGL, IQV, LLOY.L, PRX.AS | Agriculture, Banking, Communication Services, global, healthcare, technology, value |
GOOGL CNHI |
Oakmark Global Select underperformed in Q2 with Alphabet driving gains through AI initiatives and strong operating leverage, while CNH Industrial faced CEO transition and agricultural market weakness. The concentrated global portfolio maintains conviction in undervalued opportunities despite short-term volatility, with no new purchases and selective position management reflecting disciplined value approach. |
| Apr 15 2024 | 2024 Q1 | CBRE, CHTR, CNC, DHR, FI, IQV, RKT.L, SAP | Consumer Products, global, healthcare, payments, Telecommunications, value |
RKT.L IQV CNC |
Oakmark Global Select underperformed in Q1 but maintains its value-focused approach, adding healthcare exposure through IQVIA and Centene while benefiting from Fiserv's payment processing leadership. The fund opportunistically invested in quality businesses facing temporary headwinds, including Reckitt after litigation concerns and Charter amid broadband competition, expecting medium-term value realization. |
| Jan 28 2024 | 2023 Q4 | 005930.KS, AIG, BAC, CHTR, CNHI, COF, FI, GOOGL, ICE, LLOY.L | financials, global, large cap, technology, value | - | Concentrated global value fund holding 22 large-cap companies, heavily weighted toward Financials and US markets. Strong 2023 performance of 22.7% reflects disciplined approach of buying quality businesses below intrinsic value. Portfolio trades at attractive 11.4x P/E with high active share, demonstrating conviction in long-term value creation through patient capital deployment. |
| Oct 10 2023 | 2023 Q3 | CHTR, CNHI, GOOGL | Agriculture, Banking, Concentration, global, technology, Telecommunications, value |
CHTR CNHI GOOGL ACGL|APH|COO|CSGP|DKNG|GWRE|IDXX|IOT|IT|LPLA|MSCI|MTD|PCOR|ROP|TECH|VRSK |
Oakmark Global Select delivered strong annual returns through concentrated value investing in quality global businesses. Charter Communications drove performance with exceptional broadband growth, while CNH Industrial faced temporary headwinds but achieved record margins. Alphabet positioned well for AI commercialization. The fund completely exited Credit Suisse, maintaining disciplined approach to capital allocation across diversified geographic exposure. |
| Jun 30 2023 | 2023 Q2 | BABA, COP, DHR, GOOGL | China, energy, global, healthcare, technology, value |
GOOGL BABA COP DHR |
Oakmark Global Select delivered solid Q2 performance driven by Alphabet's AI momentum and operational improvements. New positions in ConocoPhillips and Danaher capitalize on energy sector value and life sciences growth. Despite Chinese headwinds pressuring Alibaba, the managers maintain conviction in undervalued global leaders with strong competitive positions and shareholder-friendly capital allocation strategies. |
| Mar 31 2023 | 2023 Q1 | AIG, BKNG, GOOGL, ICE, NFLX | AI, Exchanges, Financial Services, global, insurance, technology, value |
GOOGL AIG ICE GOOGL AIG ICE GOOGL AIG DICE |
Oakmark Global Select outperformed in Q1 2023 driven by Alphabet's AI positioning and cost discipline. Despite banking crisis headwinds affecting AIG, the fund maintains conviction in undervalued quality companies with durable advantages. New position in Intercontinental Exchange reflects focus on discounted financial infrastructure plays with attractive long-term economics. |
| Dec 31 2022 | 2022 Q4 | AMZN, COF, HCA | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
Small CapsSmall-cap equities ended 2025 on a positive but volatile note with the Russell 2000 returning 2.2% in Q4. The Federal Reserve's shift toward monetary easing represents an important inflection point for smaller companies, which tend to be more sensitive to changes in interest rates and credit conditions. Consensus expectations point to meaningful acceleration in small-cap earnings in 2026, with growth projected in the low-to-mid teens and exceeding that of large-cap companies. |
Russell 2000 Small Cap Earnings Valuations Interest Rates |
ValueSmall-cap value stocks remain attractively positioned with the strategy trading at 12.2x forward earnings versus 15.0x for the Russell 2000 Value. Growth stocks continue to trade at a meaningful premium to value across most valuation measures. Historically, periods of accelerating profits have favored value leadership, particularly within smaller-cap universes. |
Value Valuations P/E Ratio Growth Premium | |
RatesFollowing a 25 basis point cut in September, the Federal Reserve cut rates twice in Q4 to the current range of 3.50% to 3.75%. Lower borrowing costs should support refinancing activity, capital investment, and margin recovery for small-cap companies. The Fed's shift toward monetary easing represents an important inflection point for smaller companies which are more sensitive to interest rate changes. |
Federal Reserve Interest Rates Monetary Policy Credit Conditions | |
EarningsConsensus expectations point to meaningful acceleration in small-cap earnings in 2026, with growth projected in the low-to-mid teens and exceeding that of large-cap companies. This anticipated rebound reflects easier year-over-year comparisons, improving operating leverage, and broadening demand across cyclical and value-oriented sectors. Earnings growth is no longer narrowly concentrated in mega-cap AI-related companies but is beginning to broaden across the market. |
Earnings Growth Operating Leverage Cyclical Sectors | |
FinancialsWeak stock selection combined with modestly unfavorable allocation made Financials the largest detractor from relative performance during the quarter. LoanDepot weighed most heavily as elevated mortgage rates constrained refinancing activity, while LendingTree also detracted amid reduced mortgage origination volumes. Enterprise Financial Services and SouthState Bank underperformed due to net interest margin pressure and cautious loan growth outlooks. |
Banks Mortgage Net Interest Margin Loan Growth | |
| 2025 Q3 |
AIAlibaba benefited from rapid Chinese AI growth, with the company being one of the early investors in Chinese AI. The fund believes Alibaba can leverage its advanced AI capabilities and leading market position to unlock further value over time. |
AI China Technology Cloud Growth |
CloudAlibaba's Cloud segment posted healthy revenue growth with management indicating momentum is expected to continue in coming quarters. Dassault Systèmes is migrating to the cloud with related advantages that the modernized platform can provide. |
Cloud Revenue Growth Technology Software | |
BroadbandCharter Communications faced weak earnings with flat EBITDA and greater than anticipated decline in broadband subscriptions. However, broadband ARPU growth accelerated, and the company's high-capacity network is well positioned to compete long-term. |
Broadband ARPU Network Telecommunications | |
| 2025 Q2 |
Trade PolicyPresident Trump's Liberation Day announcement led to significant market volatility, with companies perceived as more exposed to tariffs falling meaningfully while others held up better. The fund actively repositioned during this period, trimming positions that performed well and buying companies where tariff concerns created wider discounts to intrinsic value. |
Tariffs Volatility Positioning Discounts Opportunity |
Electric VehiclesBMW is well-positioned for EV demand growth with higher global market share in EVs than ICE cars. Their position will be further supported by the launch of their first electric-first platform, the Neue Klasse, later this year. High degree of localization also provides better tariff protection versus peers. |
EV Platform Localization Competition Growth | |
PharmaceuticalsBayer delivered solid first-quarter results that outperformed expectations, driven primarily by Pharma segment performance, showing organizational restructuring translating to results. IQVIA faced headwinds from uncertainty about drug price controls, pharma tariffs, and government budget cuts, though intermediate and long-term prospects remain solid. |
Restructuring Performance Regulation Outlook Valuation | |
| 2025 Q1 |
ValueThe fund focuses on undervalued securities trading at meaningful discounts to intrinsic value. Examples include Alphabet trading at just 15x next year's earnings estimate and Sysco purchased at a discount to peers and historical multiples. |
Undervalued Discount Intrinsic Multiple Valuation |
Managed CareNew investment in Molina Healthcare, the fourth largest player in managed Medicaid with industry-leading growth and margins. The company has a long runway for growth via continued share gains in Medicaid and untapped opportunities in Medicare and Marketplace segments. |
Medicaid Medicare Healthcare Insurance Growth | |
CloudGoogle Cloud revenue grew 30% year-over-year despite falling slightly short of consensus expectations due to short-term capacity constraints. The long-term growth outlook for Google Cloud remains robust with strong fundamentals. |
Infrastructure Computing Growth Revenue Technology | |
AIAlphabet's new AI Overviews feature is driving higher engagement with comparable monetization. The company's world class AI capabilities can further benefit its collection of great businesses. |
Artificial Intelligence Engagement Technology Innovation Monetization | |
| 2024 Q4 |
FinancialsThe fund holds multiple financial services companies including Capital One Financial, Charles Schwab, and Elevance Health. Capital One benefited from improved credit outlook and post-election optimism about looser regulations. Schwab faces temporary headwinds from deposit outflows but offers long-term value through its scale advantages. |
Banks Consumer Finance Brokerage Managed Care Credit |
Managed CareThe fund invested in Elevance Health, viewing managed care as attractive due to health expenditures outpacing GDP and short business cycles allowing quick correction of underwriting mistakes. Current headwinds from reimbursement-cost mismatches are viewed as transitory. |
Healthcare Insurance Medical Costs Underwriting Profitability | |
BeveragesDiageo represents a global premium drinks producer with leading brands like Johnnie Walker and Guinness. The company's scale provides competitive advantages in distribution and marketing, with geographic and category diversification helping mitigate earnings volatility. |
Alcohol Premium Brands Distribution Global Consumer | |
| 2024 Q3 |
E-commerceAlibaba Group was the top contributor during the quarter following announcement of a multipronged stimulus package by the Chinese government. Despite strong performance, the market is not fully pricing in the turnaround potential for the e-commerce business or other optionality the company possesses. |
China Stimulus Turnaround |
Semiconductor CycleSamsung Electronics declined amid weaker than expected demand for memory semiconductors due to weaker personal computer and mobile industry sales. Samsung has had further delays in getting AI chips approved by major customers, though memory is viewed as a structurally growing market. |
Memory AI Demand | |
| 2024 Q2 |
Ag EquipmentCNH Industrial operates in the structurally attractive agriculture equipment market, though facing near-term weakness. The company reduced 2024 guidance due to weaker agriculture equipment market conditions, but this was consistent with forecasts and doesn't impact long-term profitability potential. |
Agriculture Equipment Machinery Farming Industrial |
| 2024 Q1 |
HealthcareThe fund invested in IQVIA Holdings, benefiting from biotech funding fears creating attractive valuations in life sciences. IQVIA is positioned to benefit from advanced therapeutics and personalized medicine trends through decentralized clinical trials and digital capabilities. The company also provides real-world evidence solutions for regulatory and reimbursement mandates. |
Life Sciences Clinical Trials Biotech Digital Health Regulatory |
Managed CareCentene represents exposure to government-sponsored healthcare programs including Medicaid, Marketplace, and Medicare Advantage. States are outsourcing Medicaid programs to managed care companies to reduce costs and improve quality. Managed Medicaid penetration has increased meaningfully and is expected to continue growing. |
Medicaid Medicare Government Programs Healthcare Insurance Managed Care | |
PaymentsFiserv was a top contributor, demonstrating leadership in merchant acquiring, issuer processing services, and core banking software. Under CEO Frank Bisignano, the company has delivered peer-leading organic growth, meaningful margin expansion, and mid-teens earnings-per-share growth while trading at a discount to the S&P 500. |
Merchant Acquiring Banking Software Payment Processing Financial Technology Organic Growth | |
| 2023 Q3 |
BroadbandCharter Communications demonstrated strong broadband subscriber growth of 77,000 in Q2, beating expectations and doubling year-over-year growth. The company's rural initiative and Spectrum One mobile offering are driving unit growth, though near-term earnings are pressured by marketing investments. |
Broadband Telecommunications Subscriber Growth Rural Mobile |
Ag EquipmentCNH Industrial faced headwinds from destocking in Brazil and production issues with new equipment, but demonstrated strong pricing power with 7% increases and record quarterly margins of 16.8% in agriculture equipment. Management expects to exceed 2024 targets despite near-term challenges. |
Agriculture Machinery Pricing Power Margins Brazil Equipment | |
AIAlphabet positioned itself as an AI-first company at an inflection point, showcasing new AI-powered consumer tools at its developer conference. The company is well-positioned to benefit from its search business scale and years of AI investment as the technology reaches commercialization. |
Artificial Intelligence Search Consumer Tools Innovation Technology | |
| 2023 Q2 |
AIAlphabet upgraded Bard to run on its more powerful PaLM language model and showcased impressive AI-powered consumer tools at its developer conference. CEO compared AI's evolution to the transition from desktop to mobile computing, with significant capital expenditure increases for AI infrastructure including data centers and servers. |
AI Machine Learning Cloud Data Centers Consumer Tools |
E-commerceAlibaba faces intense competition from short video players and traditional e-commerce companies, losing market share in China's challenging economic environment. Despite headwinds, it remains an extremely important platform generating significant free cash flow at attractive valuations. |
E-commerce China Market Share Competition | |
OilConocoPhillips represents one of the largest and most efficient U.S. exploration and production companies with extensive high-quality drilling inventory. The company is expected to return more than 100% of current market cap to shareholders over the next 10 years while growing production at mid-single-digit pace. |
Oil Exploration Production Shareholder Returns | |
BiotechnologyDanaher maintains a portfolio focused on bioprocessing, life science tools, genomics and diagnostics with secular growth positioning. Near-term pandemic-related headwinds are overshadowing attractive long-term outlook in biologics, molecular diagnostics, and genomics. |
Biotechnology Life Sciences Genomics Diagnostics | |
| 2023 Q1 |
AIAlphabet positioned as AI-first company at inflection point with management expressing excitement about AI developments in search and other areas. AI expected to drive higher revenue and profits similar to mobile computing impact. Management pushed back on concerns about AI computing costs pressuring profitability. |
Artificial Intelligence Search Computing Technology Innovation |
ValueFund focuses on companies trading at discounts to intrinsic value. Alphabet trading at lowest relative P/E since IPO when adjusted for losses and cloud asset value. AIG remains attractive despite discount. Intercontinental Exchange sells at underserved discount to peers. |
Valuation Discount Intrinsic Value P/E Ratio Undervalued | |
Capital MarketsInitiated position in Intercontinental Exchange, one of largest financial exchange operators with attractive economics across exchanges, fixed income/data services, and mortgage technology segments. Business expected to grow earnings faster than GDP over time despite near-term mortgage pressure. |
Exchanges Financial Services Data Services Trading Technology |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | Fund Letters | William C. Nygren | BAYN GR | Bayer AG | Health Care | Pharmaceuticals | Bull | Xetra | litigation, pharmaceuticals, pipeline, turnaround, valuation | Login |
| Jan 13, 2026 | Fund Letters | William C. Nygren | BABA | Alibaba Group Holding Limited | Consumer Discretionary | Internet & Direct Marketing Retail | Neutral | New York Stock Exchange | AI, cloud, ecommerce, Margins, Subsidies | Login |
| Jan 13, 2026 | Fund Letters | William C. Nygren | SAN FP | Sanofi S.A. | Health Care | Pharmaceuticals | Bull | Euronext Stock Exchange | biologics, pharma, pipeline, vaccines, valuation | Login |
| Jun 30, 2025 | Fund Letters | Oakmark Global Select Fund | DSV.CO | DSV A/S | Industrials | Air Freight & Logistics | Bull | Nasdaq Copenhagen | Acquisitions, Denmark, Freight Forwarding, Global Operations, Logistics, supply chain, Transportation | Login |
| Jun 30, 2025 | Fund Letters | Oakmark Global Select Fund | BAYRY | Bayer AG | Health Care | Pharmaceuticals | Bull | XETRA | agriculture, Crop Science, Germany, litigation, pharma, pharmaceuticals, restructuring | Login |
| Jun 30, 2025 | Fund Letters | Oakmark Global Select Fund | IQV | IQVIA Holdings Inc. | Health Care | Life Sciences Tools & Services | Bull | NYSE | analytics, Biopharma Services, Cro, Healthcare Data, life sciences, R&D, technology | Login |
| Jun 30, 2025 | Fund Letters | Oakmark Global Select Fund | BDX | Becton, Dickinson and Company | Health Care | Health Care Equipment | Bull | NYSE | diagnostics, healthcare, innovation, Laboratory Equipment, manufacturing, Medical devices, medical technology | Login |
| Jun 30, 2025 | Fund Letters | Oakmark Global Select Fund | BMW.DE | Bayerische Motoren Werke AG | Consumer Discretionary | Automobile Manufacturers | Bull | XETRA | Brand Equity, Electric Vehicles, EV Platform, Germany, Localization, Luxury Cars, Premium Automotive | Login |
| Jun 30, 2025 | Fund Letters | Oakmark Global Select Fund | BNP.PA | BNP Paribas SA | Financials | Diversified Banks | Bull | Euronext Paris | Cost control, Deposit Franchise, Diversified Bank, European Banking, france, Global Operations, Interest rates | Login |
| Mar 31, 2025 | Fund Letters | Oakmark Global Select Fund | MOH | Molina Healthcare | Health Care | Health Care Services | Bull | NYSE | Discount to Intrinsic Value, Government Programs, Healthcare services, managed care, market share gains, Medicaid, operational excellence | Login |
| Mar 31, 2025 | Fund Letters | Oakmark Global Select Fund | SYY | Sysco Corporation | Consumer Staples | Food Distributors | Bull | NYSE | Discount Valuation, food distribution, Food service, Independent Restaurants, operational efficiency, Scale Advantages, secular growth | Login |
| Mar 31, 2025 | Fund Letters | Oakmark Global Select Fund | LLOY.L | Lloyds Banking Group | Financials | Banks | Bull | London Stock Exchange | capital return, Diversified Bank, financial services, net interest margin, Share Buyback, UK Banking, value creation | Login |
| Mar 31, 2025 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | Artificial Intelligence, Cloud computing, digital advertising, growth, search engine, technology, undervalued | Login |
| Dec 31, 2024 | Fund Letters | Oakmark Global Select Fund | COF | Capital One Financial | Financials | Consumer Finance | Bull | NYSE | banking, consumer finance, credit cards, Election Impact, Loss Reserves, merger, Regulatory Relief | Login |
| Dec 31, 2024 | Fund Letters | Oakmark Global Select Fund | BAYRY | Bayer | Materials | Diversified Chemicals | Bull | OTC | agriculture, CEO change, Crop protection, Germany, litigation risk, pharmaceuticals, restructuring, turnaround | Login |
| Dec 31, 2024 | Fund Letters | Oakmark Global Select Fund | SCHW | Charles Schwab | Financials | Investment Banking & Brokerage | Bull | NYSE | Brokerage, Deposit Migration, Discount Brokerage, Interest rates, market share, Scale Advantages, Virtuous Cycle | Login |
| Dec 31, 2024 | Fund Letters | Oakmark Global Select Fund | DEO | Diageo | Consumer Staples | Distillers & Vintners | Bull | NYSE | Beverages, Destocking, Distribution, Geographic Diversification, Global Brands, Marketing Scale, premium spirits, UK | Login |
| Dec 31, 2024 | Fund Letters | Oakmark Global Select Fund | ELV | Elevance Health | Health Care | Managed Health Care | Bull | NYSE | contrarian, Cyclical, health insurance, managed care, Medical costs, reimbursement rates, Scale Advantages, Underwriting Cycle | Login |
| Sep 30, 2024 | Fund Letters | Oakmark Global Select Fund | 005930.KS | Samsung Electronics Pfd | Information Technology | Semiconductors & Semiconductor Equipment | Bull | Korea Stock Exchange | AI chips, Cyclical, Equity, Memory, semiconductors, South Korea, technology | Login |
| Sep 30, 2024 | Fund Letters | Oakmark Global Select Fund | BABA | Alibaba Group | Consumer Discretionary | Internet & Direct Marketing Retail | Bull | NYSE | China, Consumer Discretionary, e-commerce, Equity, Stimulus, technology, turnaround | Login |
| Jun 30, 2024 | Fund Letters | Oakmark Global Select Fund | CNHI | CNH Industrial N.V. | Industrials | Agricultural & Farm Machinery | Bull | NYSE | Agricultural Equipment, Construction Equipment, Cyclical, Industrials, Management Change, manufacturing, Value | Login |
| Jun 30, 2024 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | AI technology, Communication Services, Cost Reduction, growth, operating leverage, technology innovation | Login |
| Mar 31, 2024 | Fund Letters | Oakmark Global Select Fund | IQV | IQVIA Holdings | Health Care | Life Sciences Tools & Services | Bull | NASDAQ | Biotech, Clinical trials, digital health, life sciences, personalized medicine, Real-world Evidence, technology, Value | Login |
| Mar 31, 2024 | Fund Letters | Oakmark Global Select Fund | RKT.L | Reckitt Benckiser Group | Consumer Staples | Household Products | Bull | London Stock Exchange | consumer staples, Consumer-health, defensive, household products, litigation risk, margin expansion, UK, Value | Login |
| Mar 31, 2024 | Fund Letters | Oakmark Global Select Fund | CNC | Centene | Health Care | Health Care Providers & Services | Bull | NYSE | Government Programs, health insurance, Healthcare services, market share, Medicaid, Medicare Advantage, turnaround, Value | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | AIG | American International Group Inc. | Insurance - Diversified | Insurance | Bull | New York Stock Exchange | combined ratio, cost savings, financial services, General Insurance, Insurance, risk management, turnaround, underwriting | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | ICE | Intercontinental Exchange Inc. | Financial Data & Stock Exchanges | Capital Markets | Bull | New York Stock Exchange | capital allocation, Capital markets, Data Services, Financial Exchange, GDP growth, Mortgage Technology, valuation discount | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet Inc. | Internet Content & Information | Interactive Media & Services | Bull | NASDAQ | AI, Android, Cloud computing, Cost Restructuring, margin expansion, search engine, technology platform, valuation, YouTube | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | AIG | American International Group Inc. | Insurance - Diversified | Insurance | Bull | New York Stock Exchange | combined ratio, cost savings, financial services, General Insurance, Insurance, risk management, turnaround, underwriting | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | ICE | Intercontinental Exchange Inc. | Financial Data & Stock Exchanges | Capital Markets | Bull | New York Stock Exchange | capital allocation, Capital markets, Data Services, Financial Exchange, GDP growth, Mortgage Technology, valuation discount | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet Inc. | Internet Content & Information | Interactive Media & Services | Bull | NASDAQ | AI, Android, Cloud computing, Cost Restructuring, margin expansion, search engine, technology platform, valuation, YouTube | Login |
| Sep 30, 2023 | Fund Letters | Oakmark Global Select Fund | ACGL|APH|COO|CSGP|DKNG|GWRE|IDXX|IOT|IT|LPLA|MSCI|MTD|PCOR|ROP|TECH|VRSK | Credit Suisse Group | Financials | Investment Banking & Brokerage | Bear | SIX | Banking Crisis, Client Withdrawals, investment banking, Reputational Risk, restructuring, risk management, Switzerland, wealth management | Login |
| Sep 30, 2023 | Fund Letters | Oakmark Global Select Fund | CHTR | Charter Communications | Communication Services | Cable & Satellite | Bull | NASDAQ | broadband, Bundle Services, cable, Mobile, Rural Expansion, Spectrum, Subscriber Growth, telecommunications | Login |
| Sep 30, 2023 | Fund Letters | Oakmark Global Select Fund | CNHI | CNH Industrial | Industrials | Agricultural & Farm Machinery | Bull | NYSE | Agricultural Equipment, Capital Goods, Construction Equipment, Cyclical, Italy, margin expansion, Precision Agriculture, Pricing power | Login |
| Sep 30, 2023 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet | Communication Services | Interactive Media & Services | Bull | NASDAQ | AI innovation, Artificial Intelligence, Cloud computing, cost discipline, digital advertising, Search, technology, YouTube | Login |
| Jun 30, 2023 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | Artificial Intelligence, Cloud computing, digital advertising, SaaS, search engine, technology, YouTube | Login |
| Jun 30, 2023 | Fund Letters | Oakmark Global Select Fund | BABA | Alibaba Group Holding Limited | Consumer Discretionary | Internet & Direct Marketing Retail | Bull | NYSE | China, e-commerce, Free Cash Flow, restructuring, share repurchase, technology, Value | Login |
| Jun 30, 2023 | Fund Letters | Oakmark Global Select Fund | COP | ConocoPhillips | Energy | Oil, Gas & Consumable Fuels | Bull | NYSE | capital return, dividends, energy, Exploration & Production, LNG, Oil & Gas, share repurchase | Login |
| Jun 30, 2023 | Fund Letters | Oakmark Global Select Fund | DHR | Danaher Corporation | Health Care | Life Sciences Tools & Services | Bull | NYSE | biologics, Bioprocessing, diagnostics, Genomics, healthcare, life sciences, medical technology | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | GOOGL | Alphabet Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | AI, Android, Cloud computing, Cost Restructuring, margin expansion, search engine, technology platform, valuation, YouTube | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | AIG | American International Group Inc. | Financials | Insurance | Bull | NYSE | combined ratio, cost savings, financial services, General Insurance, Insurance, risk management, turnaround, underwriting | Login |
| Mar 31, 2023 | Fund Letters | Oakmark Global Select Fund | DICE | Intercontinental Exchange Inc. | Financials | Capital Markets | Bull | NYSE | capital allocation, Capital markets, Data Services, Financial Exchange, GDP growth, Mortgage Technology, valuation discount | Login |
| TICKER | COMMENTARY |
|---|---|
| BABA | Alibaba Group was the top detractor during the quarter. The China-headquartered technology conglomerate's stock price declined as it reported mixed results. The core E-commerce business continues to perform well, and Cloud revenue growth is accelerating. However, the company's earnings were negatively impacted due to significant spending on subsidies to grow their Quick Commerce business, in our opinion. We believe losses from Quick Commerce will be reduced over time and continue to believe the company is well-positioned for long-term growth, having been one of the early investors in Chinese AI. Over time, we think it can leverage its advanced capabilities and leading market position to unlock further value. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Alibaba Group 3.4%. |
| BAYRY | Bayer was the top contributor during the quarter. Two anticipated events developed in the company's favor. First, Bayer enjoyed a positive readout on the company's stroke drug, Asundexian, which met its primary endpoint in a recent phase III trial. Asundexian has the potential to be a blockbuster and support a return to growth for the Pharmaceuticals business, in our opinion. Second, the United States Solicitor General recommended that the Supreme Court hear Bayer's appeal in Durnell v. Monsanto, increasing the odds that the RoundUp matter is heard by the Court. Both events support our investment thesis for Bayer as management works to turn around fundamental performance and contain litigation risk. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Bayer 4.8%. |
| CHTR | Charter Communications Cl A was listed as one of the top detractors for the fourth quarter. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Charter Communications Cl A 2.3%. |
| CNHI | CNH Industrial was listed as one of the top detractors for the fourth quarter. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: CNH Industrial 4.4%. |
| GOOGL | Alphabet Cl A was listed as one of the top contributors for the fourth quarter. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Alphabet Cl A 4.0%. |
| IQV | IQVIA Holdings was listed as one of the top contributors for the fourth quarter. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: IQVIA Holdings 6.3%. |
| MBG.DE | Mercedes-Benz Group was listed as a final sale during the quarter. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Mercedes-Benz Group 0%. |
| RHHBY | Roche Holding was listed as a final sale during the quarter. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Roche Holding 0%. |
| SNY | Sanofi is a global pharmaceutical company developing biologics, vaccines and healthcare solutions to prevent and treat a wide range of conditions in immunology, hemophilia, rare diseases and general medicine. The company is best-known for its blockbuster drug, Dupixent, a fast-growing biologic that provides doctors with a single, versatile therapy for multiple inflammatory conditions, combining strong efficacy with a clean safety profile. Beyond Dupixent, we think there is a lot to be excited about as management has prioritized innovation by aggressively investing in research and development to cultivate a pipeline of promising products. Despite strong fundamentals, the stock has been weighed down by a volatile year for the vaccine market, investor concerns about patent cliffs and minimal value ascription to its pipeline. This created the opportunity for us to invest in a company we believe is improving, with a long runway for future growth as vaccine markets normalize and new product potential is realized. The securities mentioned above comprise the following percentages of the Oakmark Global Select Fund's total net assets as of 12/31/2025: Sanofi 5.0%. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||